Nevro Corp Company Profile (NYSE:NVRO)

About Nevro Corp (NYSE:NVRO)

Nevro Corp logoNevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, it was investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain. The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Symbol: NYSE:NVRO
  • CUSIP: N/A
  • Web: www.nevro.com
Capitalization:
  • Market Cap: $2.16 billion
  • Outstanding Shares: 29,295,000
Average Prices:
  • 50 Day Moving Avg: $84.17
  • 200 Day Moving Avg: $85.90
  • 52 Week Range: $66.55 - $106.93
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 820.44
  • P/E Growth: -2.99
Sales & Book Value:
  • Annual Revenue: $255.29 million
  • Price / Sales: 8.47
  • Book Value: $8.29 per share
  • Price / Book: 8.91
Profitability:
  • EBIDTA: ($25,290,000.00)
  • Net Margins: -18.91%
  • Return on Equity: -14.57%
  • Return on Assets: -9.98%
Debt:
  • Debt-to-Equity Ratio: 0.55%
  • Current Ratio: 11.83%
  • Quick Ratio: 9.71%
Misc:
  • Average Volume: 579,954 shs.
  • Beta: -0.75
  • Short Ratio: 10.75
 

Frequently Asked Questions for Nevro Corp (NYSE:NVRO)

What is Nevro Corp's stock symbol?

Nevro Corp trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

How were Nevro Corp's earnings last quarter?

Nevro Corp (NYSE:NVRO) issued its earnings results on Monday, May, 8th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.24. The company had revenue of $68.40 million for the quarter, compared to analysts' expectations of $68.71 million. Nevro Corp had a negative net margin of 18.91% and a negative return on equity of 14.57%. The company's revenue was up 64.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.33) earnings per share. View Nevro Corp's Earnings History.

Where is Nevro Corp's stock going? Where will Nevro Corp's stock price be in 2017?

13 brokerages have issued 12-month price targets for Nevro Corp's stock. Their predictions range from $85.00 to $120.00. On average, they expect Nevro Corp's share price to reach $101.90 in the next year. View Analyst Ratings for Nevro Corp.

What are analysts saying about Nevro Corp stock?

Here are some recent quotes from research analysts about Nevro Corp stock:

  • 1. According to Zacks Investment Research, "Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza (R) spinal cord stimulation (SCS) system for the treatment of chronic pain. Senza, HF10, Nevro and the Nevro logo are trademarks of the company. Nevro Corp. is headquartered in Menlo Park, California. " (5/11/2017)
  • 2. Northland Securities analysts commented, "The widely awaited release of Boston Scientific's ACCELERATE Study data on the Q4 call today, was a downer. Strangely enough, the company stated on its call that it "would continue enrolling patients in the trial, expects enrollment to finish by end of FY17, and data release by mid-2018." Suffice it to say, the anti-climax will be perceived as something being off in the ACCELERATE Study, hence being positive for Nevro."The analyst speculated that something is off in the ACCELERATE study, causing a delay in datarelease. Here are some thoughts / questions:Is Boston Sci increasing the sample size in the trial ?Was there a sub-group analysis done and investigators realized that the bellcurve on lead placements was not on T8 - T10 locations, hence pain relief was sub-optimal? Will there now be more anatomical placement on T8 - T10 with its HF arm? In essence, is Boston Sci converging on Nevro's "secret sauce" (2/2/2017)

Who are some of Nevro Corp's key competitors?

Who owns Nevro Corp stock?

Nevro Corp's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (7.55%), Vanguard Group Inc. (6.63%), BlackRock Inc. (5.40%), Goldman Sachs Group Inc. (5.07%), Alliancebernstein L.P. (4.19%) and OppenheimerFunds Inc. (2.64%). Company insiders that own Nevro Corp stock include & Johnson Johnson, Andre Walker, Andrew H Galligan, Bay City Capital Llc, Brad Vale, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro Corp.

Who sold Nevro Corp stock? Who is selling Nevro Corp stock?

Nevro Corp's stock was sold by a variety of institutional investors in the last quarter, including Metropolitan Life Insurance Co. NY, FMR LLC, Next Century Growth Investors LLC, Alliancebernstein L.P., American Century Companies Inc., Wellington Management Group LLP, Artisan Partners Limited Partnership and Kornitzer Capital Management Inc. KS. Company insiders that have sold Nevro Corp stock in the last year include Andre Walker, Andrew H Galligan, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Insider Buying and Selling for Nevro Corp.

Who bought Nevro Corp stock? Who is buying Nevro Corp stock?

Nevro Corp's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Victory Capital Management Inc., Perceptive Advisors LLC, Janus Capital Management LLC, OppenheimerFunds Inc., Gilder Gagnon Howe & Co. LLC, Columbus Circle Investors and Blue Jay Capital Management LLC. View Insider Buying and Selling for Nevro Corp.

How do I buy Nevro Corp stock?

Shares of Nevro Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Nevro Corp stock cost?

One share of Nevro Corp stock can currently be purchased for approximately $73.84.

Analyst Ratings

Consensus Ratings for Nevro Corp (NYSE:NVRO) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.77)
Consensus Price Target: $101.90 (38.00% upside)

Analysts' Ratings History for Nevro Corp (NYSE:NVRO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/24/2017ValuEngineDowngradeHold -> SellLowView Rating Details
5/14/2017B. RileyDowngradeNeutral$85.00LowView Rating Details
5/9/2017Northland SecuritiesReiterated RatingBuy$96.00HighView Rating Details
3/23/2017Canaccord GenuityInitiated CoverageBuy$120.00MediumView Rating Details
2/24/2017Leerink SwannBoost Price TargetOutperform$100.00 -> $110.00N/AView Rating Details
8/11/2016Piper Jaffray CompaniesReiterated RatingOverweight$98.00 -> $112.00N/AView Rating Details
8/9/2016JPMorgan Chase & Co.Boost Price TargetOverweight$84.00 -> $100.00N/AView Rating Details
8/9/2016JMP SecuritiesBoost Price TargetMarket Outperform$90.00 -> $110.00N/AView Rating Details
8/9/2016BMO Capital MarketsReiterated RatingBuy$100.00N/AView Rating Details
8/8/2016Bank of America CorpInitiated CoverageBuy$100.00N/AView Rating Details
7/18/2016William BlairReiterated RatingOutperformN/AView Rating Details
7/12/2016Wells Fargo & CoInitiated CoverageOutperformN/AView Rating Details
6/29/2016Morgan StanleyReiterated RatingBuy$86.00N/AView Rating Details
5/16/2016Sterne Agee CRTReiterated RatingBuyN/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Nevro Corp (NYSE:NVRO)
Earnings by Quarter for Nevro Corp (NYSE:NVRO)
Earnings History by Quarter for Nevro Corp (NYSE:NVRO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.26)($0.50)$68.71 million$68.40 millionViewListenView Earnings Details
2/23/2017Q416($0.20)($0.34)$66.41 million$70.50 millionViewN/AView Earnings Details
11/7/2016Q316($0.39)($0.14)$58.05 million$60.92 millionViewListenView Earnings Details
8/8/2016Q216($0.47)($0.31)$45.11 million$55.40 millionViewN/AView Earnings Details
5/9/2016Q116($0.65)($0.33)$33.48 million$41.65 millionViewN/AView Earnings Details
2/29/2016Q415($0.56)($0.51)$32.88 million$33.10 millionViewListenView Earnings Details
11/9/2015Q315($0.75)($0.70)$12.51 million$15.40 millionViewN/AView Earnings Details
8/6/2015Q215($0.89)($0.77)$9.65 million$11.40 millionViewN/AView Earnings Details
5/11/2015Q1($0.54)($0.57)$8.20 million$9.66 millionViewListenView Earnings Details
3/18/2015Q4 2014($0.51)($0.59)$9.72 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nevro Corp (NYSE:NVRO)
Current Year EPS Consensus Estimate: $-0.99 EPS
Next Year EPS Consensus Estimate: $0.09 EPS

Dividends

Dividend History for Nevro Corp (NYSE:NVRO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Nevro Corp (NYSE:NVRO)
Insider Ownership Percentage: 12.10%
Insider Trades by Quarter for Nevro Corp (NYSE:NVRO)
Institutional Ownership by Quarter for Nevro Corp (NYSE:NVRO)
Insider Trades by Quarter for Nevro Corp (NYSE:NVRO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Andrew H. GalliganCFOSell7,500$75.30$564,750.00View SEC Filing  
5/2/2017Michael F DemaneDirectorSell29,800$96.07$2,862,886.00View SEC Filing  
5/1/2017Rami ElghandourCEOSell10,000$95.03$950,300.00View SEC Filing  
4/4/2017Michael EnxingVPSell1,500$93.53$140,295.00View SEC Filing  
4/4/2017Michael F DemaneDirectorSell22,200$93.39$2,073,258.00View SEC Filing  
4/3/2017Andrew H. GalliganCFOSell30,000$94.46$2,833,800.00View SEC Filing  
3/6/2017Michael EnxingVPSell38,500$91.01$3,503,885.00View SEC Filing  
3/3/2017Wilfred E JaegerDirectorSell43,980$95.03$4,179,419.40View SEC Filing  
1/4/2017Michael EnxingVPSell1,500$75.88$113,820.00View SEC Filing  
12/5/2016Michael EnxingVPSell1,500$76.38$114,570.00View SEC Filing  
11/15/2016Andrew H GalliganCFOSell7,500$86.90$651,750.00View SEC Filing  
10/10/2016Rami ElghandourCEOSell3,000$100.00$300,000.00View SEC Filing  
10/6/2016Michael F DemaneDirectorSell139,514$97.46$13,597,034.44View SEC Filing  
10/4/2016Michael EnxingVPSell1,500$99.31$148,965.00View SEC Filing  
8/22/2016Doug AlleavitchVPSell3,000$100.00$300,000.00View SEC Filing  
8/22/2016Wilfred E JaegerDirectorSell154,840$97.79$15,141,803.60View SEC Filing  
8/17/2016Wilfred E JaegerDirectorSell155,160$97.31$15,098,619.60View SEC Filing  
8/15/2016Andrew H GalliganCFOSell7,500$97.71$732,825.00View SEC Filing  
8/10/2016Doug AlleavitchVPSell2,500$95.00$237,500.00View SEC Filing  
8/9/2016Michael F DemaneDirectorSell26,667$91.50$2,440,030.50View SEC Filing  
8/4/2016Michael EnxingVPSell1,500$82.06$123,090.00View SEC Filing  
7/29/2016Doug AlleavitchVPSell1,000$85.00$85,000.00View SEC Filing  
7/29/2016Michael F DemaneDirectorSell13,333$84.00$1,119,972.00View SEC Filing  
7/11/2016Doug AlleavitchVPSell2,000$80.00$160,000.00View SEC Filing  
7/11/2016Michael F DemaneDirectorSell13,333$79.00$1,053,307.00View SEC Filing  
7/5/2016Michael EnxingVPSell1,500$75.39$113,085.00View SEC Filing  
7/1/2016Michael F DemaneDirectorSell13,333$74.00$986,642.00View SEC Filing  
6/8/2016Doug AlleavitchVPSell1,000$75.00$75,000.00View SEC Filing  
6/8/2016Rami ElghandourCEOSell7,000$76.59$536,130.00View SEC Filing  
6/6/2016Michael EnxingVPSell1,500$73.29$109,935.00View SEC Filing  
6/2/2016Andre WalkerVPSell4,000$73.50$294,000.00View SEC Filing  
6/1/2016Doug AlleavitchVPSell500$72.00$36,000.00View SEC Filing  
5/18/2016Wilfred E JaegerDirectorSell112,983$64.68$7,307,740.44View SEC Filing  
5/16/2016Andrew H GalliganCFOSell10,000$64.78$647,800.00View SEC Filing  
5/16/2016Michael F DemaneCEOSell39,999$64.77$2,590,735.23View SEC Filing  
5/12/2016Rami ElghandourPresidentSell7,000$63.93$447,510.00View SEC Filing  
5/4/2016Michael EnxingVPSell1,500$65.06$97,590.00View SEC Filing  
4/4/2016Michael EnxingVPSell8,767$61.59$539,959.53View SEC Filing  
4/1/2016Rami ElghandourPresidentSell7,000$60.99$426,930.00View SEC Filing  
1/11/2016Andre WalkerVPSell7,987$70.75$565,080.25View SEC Filing  
1/4/2016Doug AlleavitchVPSell2,514$66.47$167,105.58View SEC Filing  
12/17/2015Andre WalkerVPSell13$69.00$897.00View SEC Filing  
12/7/2015Rami ElghandourPresidentSell3,500$61.82$216,370.00View SEC Filing  
12/2/2015Andre WalkerVPSell1,000$64.00$64,000.00View SEC Filing  
12/1/2015Andre WalkerVPSell8,000$59.50$476,000.00View SEC Filing  
11/30/2015Andre WalkerVPSell6,000$58.50$351,000.00View SEC Filing  
11/30/2015Rami ElghandourPresidentSell3,500$60.00$210,000.00View SEC Filing  
11/24/2015Andre WalkerVPSell1,000$55.00$55,000.00View SEC Filing  
11/23/2015Andre WalkerVPSell1,000$54.00$54,000.00View SEC Filing  
11/23/2015Wilfred E JaegerDirectorSell25,000$53.48$1,337,000.00View SEC Filing  
11/18/2015Wilfred E JaegerDirectorSell175,000$52.24$9,142,000.00View SEC Filing  
11/16/2015Michael F DemaneCEOSell26,667$50.52$1,347,216.84View SEC Filing  
11/13/2015Brad ValeDirectorBuy2,000$50.76$101,520.00View SEC Filing  
9/17/2015Andre WalkerVPSell4,000$50.75$203,000.00View SEC Filing  
9/2/2015Michael F DemaneCEOSell40,001$45.11$1,804,445.11View SEC Filing  
6/8/2015& Johnson JohnsonMajor ShareholderSell1,010,265$47.94$48,432,104.10View SEC Filing  
6/8/2015Bay City Capital LlcInsiderSell491,835$47.94$23,578,569.90View SEC Filing  
6/8/2015Wilfred E JaegerDirectorSell393,468$47.94$18,862,855.92View SEC Filing  
11/12/2014& Johnson JohnsonMajor ShareholderBuy40,000$18.00$720,000.00View SEC Filing  
11/12/2014A/S NovoInsiderBuy215,000$18.00$3,870,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Nevro Corp (NYSE:NVRO)
Latest Headlines for Nevro Corp (NYSE:NVRO)
Source:
DateHeadline
americanbankingnews.com logoNevro Corp (NVRO) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - May 24 at 3:56 PM
americanbankingnews.com logoZacks: Analysts Anticipate Nevro Corp (NVRO) Will Announce Quarterly Sales of $73.83 Million
www.americanbankingnews.com - May 17 at 12:02 PM
americanbankingnews.com logoNevro Corp (NVRO) CFO Sells $564,750.00 in Stock
www.americanbankingnews.com - May 16 at 7:33 PM
americanbankingnews.com logo-$0.28 EPS Expected for Nevro Corp (NVRO) This Quarter
www.americanbankingnews.com - May 15 at 9:24 AM
americanbankingnews.com logoB. Riley Downgrades Nevro Corp (NVRO) to Neutral
www.americanbankingnews.com - May 14 at 10:16 AM
americanbankingnews.com logoNevro Corp (NVRO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 12 at 7:40 AM
americanbankingnews.com logoNevro Corp (NVRO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 11 at 8:04 AM
finance.yahoo.com logoEdited Transcript of NVRO earnings conference call or presentation 8-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 11:59 AM
nasdaq.com logoOversold Conditions For Nevro (NVRO)
www.nasdaq.com - May 9 at 6:32 PM
finance.yahoo.com logoNevro Corp. Just Tumbled By As Much As 12% -- Here's Why
finance.yahoo.com - May 9 at 6:32 PM
finance.yahoo.com logoMedtech Player Losses Double That Of Views; Shares Tumble
finance.yahoo.com - May 9 at 6:32 PM
americanbankingnews.com logoNevro Corp (NVRO) Releases Quarterly Earnings Results, Misses Expectations By $0.24 EPS
www.americanbankingnews.com - May 9 at 4:02 PM
americanbankingnews.com logoNevro Corp (NVRO) Rating Reiterated by Northland Securities
www.americanbankingnews.com - May 9 at 11:32 AM
streetinsider.com logoB. Riley Downgrades Nevro Corp (NVRO) to Neutral Citing Slower US-Based Revenue Growth
www.streetinsider.com - May 9 at 11:26 AM
finance.yahoo.com logoNevro Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 6:23 PM
marketbeat.com logoNevro reports 1Q loss
marketbeat.com - May 8 at 4:34 PM
finance.yahoo.com logoMedical Product Q1 Earnings on May 8: ITGR, OPK & More
finance.yahoo.com - May 5 at 7:13 PM
americanbankingnews.com logoNevro Corp (NVRO) Receives Media Impact Score of -0.08
www.americanbankingnews.com - May 4 at 12:08 PM
americanbankingnews.com logoRami Elghandour Sells 10,000 Shares of Nevro Corp (NVRO) Stock
www.americanbankingnews.com - May 3 at 7:00 PM
americanbankingnews.com logoMichael F. Demane Sells 29,800 Shares of Nevro Corp (NVRO) Stock
www.americanbankingnews.com - May 3 at 6:56 PM
finance.yahoo.com logoNevro to Present at the Bank of America Merrill Lynch 2017 Health Care Conference - Yahoo Finance
finance.yahoo.com - May 2 at 4:44 PM
finance.yahoo.com logoNevro to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
finance.yahoo.com - May 2 at 4:44 PM
finance.yahoo.com logoNevro Corp. – Value Analysis (NYSE:NVRO) : May 1, 2017
finance.yahoo.com - May 1 at 5:52 PM
americanbankingnews.com logoNevro Corp (NVRO) Earning Somewhat Favorable Media Coverage, Report Finds
www.americanbankingnews.com - April 30 at 9:40 AM
finance.yahoo.com logoNevro Corp. breached its 50 day moving average in a Bullish Manner : NVRO-US : April 28, 2017
finance.yahoo.com - April 28 at 8:46 AM
americanbankingnews.com logo$68.09 Million in Sales Expected for Nevro Corp (NVRO) This Quarter
www.americanbankingnews.com - April 26 at 12:16 PM
finance.yahoo.com logoNevro to Report Operating Results for the First Quarter 2017
finance.yahoo.com - April 25 at 5:43 AM
americanbankingnews.com logo-$0.26 EPS Expected for Nevro Corp (NVRO) This Quarter
www.americanbankingnews.com - April 24 at 4:24 PM
americanbankingnews.com logoNevro Corp (NVRO) Earns Daily Coverage Optimism Score of -0.20
www.americanbankingnews.com - April 24 at 2:01 PM
finance.yahoo.com logoETFs with exposure to Nevro Corp. : April 21, 2017
finance.yahoo.com - April 21 at 6:48 PM
americanbankingnews.com logoNevro Corp (NVRO) Receiving Somewhat Negative Press Coverage, Analysis Shows
www.americanbankingnews.com - April 21 at 5:48 PM
americanbankingnews.com logoNevro Corp (NVRO) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 17 at 10:14 AM
americanbankingnews.com logoNevro Corp (NVRO) Receiving Somewhat Positive Media Coverage, Analysis Shows
www.americanbankingnews.com - April 15 at 2:55 PM
nasdaq.com logoNevro Becomes Oversold (NVRO)
www.nasdaq.com - April 12 at 7:52 PM
finance.yahoo.com logoETFs with exposure to Nevro Corp. : April 7, 2017
finance.yahoo.com - April 7 at 7:21 PM
finance.yahoo.com logoNevro Corp. breached its 50 day moving average in a Bearish Manner : NVRO-US : April 6, 2017
finance.yahoo.com - April 7 at 11:38 AM
americanbankingnews.com logoMichael Enxing Sells 1,500 Shares of Nevro Corp (NVRO) Stock
www.americanbankingnews.com - April 5 at 8:52 PM
americanbankingnews.com logoInsider Selling: Nevro Corp (NVRO) CFO Sells 30,000 Shares of Stock
www.americanbankingnews.com - April 5 at 8:04 PM
americanbankingnews.com logoNevro Corp (NVRO) Director Michael F. Demane Sells 22,200 Shares
www.americanbankingnews.com - April 5 at 8:03 PM
seekingalpha.com logoNevro: Increased Access To HF10 Therapy Will Power Stock Price
seekingalpha.com - March 29 at 7:37 PM
americanbankingnews.com logoNevro Corp (NVRO) Now Covered by Canaccord Genuity
www.americanbankingnews.com - March 29 at 8:47 AM
americanbankingnews.com logoCanaccord Genuity Begins Coverage on Nevro Corp (NVRO)
www.americanbankingnews.com - March 29 at 8:41 AM
nasdaq.com logoCommit To Purchase Nevro Corp At $75, Earn 10.2% Annualized Using Options
www.nasdaq.com - March 27 at 6:26 PM
americanbankingnews.com logoNevro Corp (NVRO) Now Covered by Analysts at Canaccord Genuity
www.americanbankingnews.com - March 23 at 2:10 PM
prnewswire.com logoRecent Developments in the Electrophysiology Markets
www.prnewswire.com - March 22 at 9:10 AM
americanbankingnews.com logoNevro Corp (NVRO) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 21 at 12:34 PM
baystreet.ca logoBlog Coverage German and UK Courts Rule in Favor of Boston Scientifics' Patent Related Litigation with Edwards Lifesciences
www.baystreet.ca - March 10 at 9:22 AM
finance.yahoo.com logoNEVRO CORP Financials
finance.yahoo.com - March 1 at 7:07 PM
streetinsider.com logoNevro Corp (NVRO) PT Raised to $110 at Leerink Partners - StreetInsider.com
www.streetinsider.com - February 24 at 8:55 AM
finance.yahoo.com logoEdited Transcript of NVRO earnings conference call or presentation 23-Feb-17 9:30pm GMT
finance.yahoo.com - February 24 at 8:55 AM

Social

Chart

Nevro Corp (NVRO) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff